Musculoskeletal Disorders, Pain Medication, and in-Hospital Mortality among Patients with COVID-19 in South Korea: A Population-Based Cohort Study

Oh et al., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18136804

Oh et al., Musculoskeletal Disorders, Pain Medication, and in-Hospital Mortality among Patients with COVID-19 in South.., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18136804

Jun 2021 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 7,713 COVID-19 patients in Korea, showing no significant difference in mortality with paracetamol use. Paracetamol is also known as acetaminophen.

Important missing comments or errors? Let us know.

risk of death, 1.9% lower, RR 0.98, p = 0.97, treatment 58, control 7,655, adjusted per study, odds ratio converted to relative risk, multivariable, control prevalance approximated with overall prevalence.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Oh et al., 24 Jun 2021, retrospective, South Korea, peer-reviewed, 5 authors, study period 1 January, 2020 - 4 June, 2020.

Contact: uchic@ncc.re.kr (corresponding author), airohtak@hotmail.com, songoficu@outlook.kr, leejoon.com@gmail.com, ytjeon@snubh.org.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Acetaminophen All

Musculoskeletal Disorders, Pain Medication, and in-Hospital Mortality among Patients with COVID-19 in South Korea: A Population-Based Cohort Study

Tak-Kyu Oh, In-Ae Song, Joon Lee, Woosik Eom, Young-Tae Jeon

International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18136804

We aimed to investigate whether comorbid musculoskeletal disorders (MSD)s and pain medication use was associated with in-hospital mortality among patients with coronavirus disease 2019 . Adult patients (≥20 years old) with a positive COVID-19 diagnosis until 5 June 2020 were included in this study, based on the National Health Insurance COVID-19 database in South Korea. MSDs included osteoarthritis, neck pain, lower back pain, rheumatoid arthritis, and others, while pain medication included paracetamol, gabapentin, pregabalin, glucocorticoid, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids (strong and weak opioids), and benzodiazepine. Primary endpoint was in-hospital mortality. A total of 7713 patients with COVID-19 were included, and in-hospital mortality was observed in 248 (3.2%) patients. In multivariate logistic regression analysis, no MSDs (p > 0.05) were significantly associated with in-hospital mortality. However, in-hospital mortality was 12.73 times higher in users of strong opioids (odds ratio: 12.73, 95% confidence interval: 2.44-16.64; p = 0.002), while use of paracetamol (p = 0.973), gabapentin or pregabalin (p = 0.424), glucocorticoid (p = 0.673), NSAIDs (p = 0.979), weak opioids (p = 0.876), and benzodiazepine (p = 0.324) was not associated with in-hospital mortality. In South Korea, underlying MSDs were not associated with increased in-hospital mortality among patients with COVID-19. However, use of strong opioids was significantly associated with increased in-hospital mortality among the patients.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 .3390/ijerph18136804/s1, Table S1 : ICD-10 codes and Table S2 : The ICD-10 codes used by comorbidity to compute the Charlson comorbidity index. Informed Consent Statement: Informed consent was waived by the IRB, as the analyses were performed retrospectively using anonymized data derived from the South Korean NHIS database. Conflicts of Interest: The authors declare no conflict of interest.

References

Bedford, Enria, Giesecke, Heymann, Ihekweazu et al., COVID-19: Towards controlling of a pandemic, Lancet, doi:10.1016/S0140-6736(20)30673-5

Briggs, Woolf, Dreinhöfer, Homb, Hoy et al., Reducing the global burden of musculoskeletal conditions, Bull. World Heal. Organ, doi:10.2471/BLT.17.204891

Dagan, Barda, Kepten, Miron, Perchik et al., BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, N. Engl. J. Med, doi:10.1056/NEJMoa2101765

Diasso, Birke, Nielsen, Main, Højsted et al., The effects of long-term opioid treatment on the immune system in chronic non-cancer pain patients: A systematic review, Eur. J. Pain, doi:10.1002/ejp.1506

Elm, Altman, Egger, Pocock, Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies, Ann. Intern. Med, doi:10.7326/0003-4819-147-8-200710160-00010

Flint, Janowitz, Connell, Roberts, Denton et al., Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity, Cell Metab, doi:10.1016/j.cmet.2016.10.010

Fredi, Cavazzana, Moschetti, Andreoli, Franceschini et al., COVID-19 in patients with rheumatic diseases in northern Italy: A single-centre observational and case-control study, Lancet Rheumatol, doi:10.1016/S2665-9913(20)30169-7

Fung, Babik, COVID-19 in Immunocompromised Hosts: What We Know So Far, Clin. Infect. Dis, doi:10.1093/cid/ciaa863

Generaal, Vogelzangs, Macfarlane, Geenen, Smit et al., Basal inflammation and innate immune response in chronic multisite musculoskeletal pain, Pain, doi:10.1016/j.pain.2014.05.007

Gomes, Tadrous, Mamdani, Paterson, Juurlink, The Burden of Opioid-Related Mortality in the United States, JAMA Netw. Open, doi:10.1001/jamanetworkopen.2018.0217

Greenland, Mansournia, Altman, Sparse data bias: A problem hiding in plain sight, BMJ, doi:10.1136/bmj.i1981

Haberman, Axelrad, Chen, Castillo, Yan et al., Covid-19 in Immune-Mediated Inflammatory Diseases-Case Series from New York, N. Engl. J. Med, doi:10.1056/NEJMc2009567

Haberman, Castillo, Chen, Yan, Ramirez et al., COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes, Arthritis Rheumatol, doi:10.1002/art.41456

Kim, Fine, Li, Kimmel, Ngo et al., Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study, PLoS Med, doi:10.1371/journal.pmed.1003247

Knoll, Wonodi, Oxford-AstraZeneca COVID-19 vaccine efficacy, Lancet, doi:10.1016/S0140-6736(20)32623-4

Mackinnon, Socías, Bardwell, COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings, J. Subst. Abus Treat, doi:10.1016/j.jsat.2020.108153

Manuel, Estabrook, The American Society of Transplantation Infectious Diseases Community of Practice. RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, Clin. Transplant, doi:10.1111/ctr.13511

Oh, Jeon, Choi, Trends in chronic opioid use and association with five-year survival in South Korea: A populationbased cohort study, Br. J. Anaesth, doi:10.1016/j.bja.2019.08.012

Oh, Song, Trends in long-term glucocorticoid use and risk of 5-year mortality: A historical cohort study in South Korea, Endocrine, doi:10.1007/s12020-020-02382-6

Pereira, Lawlor, Vigano, Dorgan, Bruera, Equianalgesic Dose Ratios for Opioids: A Critical Review and Proposals for Long-Term Dosing, J. Pain Symptom Manag, doi:10.1016/S0885-3924(01)00294-9

Pierce, Bird, Hickman, Millar, National record linkage study of mortality for a large cohort of opioid users ascertained by drug treatment or criminal justice sources in England, 2005-2009, Drug Alcohol Depend, doi:10.1016/j.drugalcdep.2014.09.782

Ray, Chung, Murray, Hall, Stein, Prescription of Long-Acting Opioids and Mortality in Patients with Chronic Noncancer Pain, JAMA, doi:10.1001/jama.2016.7789

Salas, Hotman, Stricker, Confounding by Indication: An Example of Variation in the Use of Epidemiologic Terminology, Am. J. Epidemiol, doi:10.1093/oxfordjournals.aje.a009758

Schimmel, Manini, Opioid Use Disorder and COVID-19: Biological Plausibility for Worsened Outcomes, Subst. Use Misuse, doi:10.1080/10826084.2020.1791184

Schwetz, Calder, Rosenthal, Kattakuzhy, Fauci, Opioids and Infectious Diseases: A Converging Public Health Crisis, J. Infect. Dis, doi:10.1093/infdis/jiz133

Shah, Kuo, Baillargeon, Raji, The impact of long-term opioid use on the risk and severity of COVID-19, J. Opioid Manag, doi:10.5055/jom.2020.0597

Shi, Wang, Shao, Huang, Gan et al., COVID-19 infection: The perspectives on immune responses, Cell Death Differ, doi:10.1038/s41418-020-0530-3

Waghmare, Englund, Boeckh, How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation, Blood, doi:10.1182/blood-2016-01-634873

Wang, Kaelber, Xu, Volkow, COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States, Mol. Psychiatry, doi:10.1038/s41380-020-00880-7

Weisberg, Gordon, Barry, Becker, Crystal et al., Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients, J. Acquir. Immune Defic. Syndr, doi:10.1097/QAI.0000000000000591

Wilson, Ramage, Fagan, A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder, J. Rural. Heal, doi:10.1111/jrh.12438

Wolfe, Caplan, Michaud, Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy, Arthritis Rheum, doi:10.1002/art.21568

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit